TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Bank of America Corp DE

Bank of America Corp DE decreased its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 86.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 230,939 shares of the biopharmaceutical company's stock after selling 1,466,433 shares during the quarter. Bank of America Corp DE owned about 0.15% of TG Therapeutics worth $6,951,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of the company. Quadrant Capital Group LLC boosted its stake in TG Therapeutics by 137.1% in the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock worth $51,000 after buying an additional 975 shares during the last quarter. Blue Trust Inc. boosted its stake in TG Therapeutics by 24.5% in the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after buying an additional 371 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in TG Therapeutics by 512.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock worth $60,000 after buying an additional 1,594 shares during the last quarter. Jones Financial Companies Lllp boosted its stake in TG Therapeutics by 460.7% in the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock worth $64,000 after buying an additional 1,737 shares during the last quarter. Finally, Synergy Asset Management LLC acquired a new stake in TG Therapeutics in the 4th quarter worth about $75,000. Institutional investors and hedge funds own 58.58% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. HC Wainwright reissued a "buy" rating and issued a $55.00 price target on shares of TG Therapeutics in a research note on Tuesday, March 4th. Wall Street Zen upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $40.80.

TG Therapeutics Trading Down 1.1%

Shares of TG Therapeutics stock traded down $0.39 during trading hours on Friday, reaching $35.32. The stock had a trading volume of 1,825,344 shares, compared to its average volume of 2,979,020. The firm has a 50 day simple moving average of $37.40 and a two-hundred day simple moving average of $34.43. The firm has a market capitalization of $5.61 billion, a price-to-earnings ratio of -353.16 and a beta of 2.21. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a 1 year low of $15.16 and a 1 year high of $46.48.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.16). The company had revenue of $120.86 million for the quarter, compared to analysts' expectations of $117.07 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business's quarterly revenue was up 90.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.07) earnings per share. As a group, equities research analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.